Cambridge University Hospitals NHS Foundation Trust
N/A
1997-07-01
The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than
aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.
The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than
aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.
The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than
aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
Completed
Shire
Phase 4
2006-01-13
Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to
be produced. Platelets are small cells carried around in the blood, which help form blood
clots. When patients have too many platelets, there is a risk of blood clots forming
unnecessarily and excessive bleeding. The aim of this study is to gain additional information
on the safety profile of Anagrelide (Xagrid(r)) and Hydroxyurea (also known as
hydroxycarbamide).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
